CompletedPhase 2NCT04128722

TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN

Studying Microcystic lymphatic malformation

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University Hospital, Tours
Principal Investigator: Annabel MARUANI, MD-PhD
University Hospital of TOURS;INSERM 1246 SPHERE
Intervention: Sirolimus Oral Liquid Product 1mg/mL(drug)
Enrollment: 12 target
Eligibility: 5 years · All sexes
Timeline: 2020 – 2025

Study locations (2)

Univsersity of TOURS _ Service de Dermatologie, Tours, Indre et Loire, France
Hospital NECKER -AP-HP - Dermatology, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04128722 on ClinicalTrials.gov

Other trials for Microcystic lymphatic malformation

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT06239480
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics, Inc.

See all trials for Microcystic lymphatic malformation →

← Back to all trials